These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 10890792)

  • 21. [Economic impact of cardiac resynchronization therapy in patients with heart failure. Available evidence and evaluation of the CRT-Eucomed model for analysis of cost-effectiveness].
    Fattore G; Landolina M; Bontempi L; Cacciatore G; Curnis A; Gulizia M; Padeletti L; Mazzei L; Tavazzi L;
    Ital Heart J Suppl; 2005 Dec; 6(12):796-803. PubMed ID: 16444923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmaco-economic evaluation of drug therapy osteoporosis. A literature review].
    Christensen PM; Brøsen K; Brixen KT; Beck-Nielsen H; Søgaard J; Kristiansen IS
    Ugeskr Laeger; 2002 Mar; 164(10):1339-45. PubMed ID: 11894425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of quality-adjusted life-years in cost-effectiveness studies.
    Sculpher M
    Allergy; 2006 May; 61(5):527-30. PubMed ID: 16629779
    [No Abstract]   [Full Text] [Related]  

  • 24. The value of aortic valve replacement in elderly patients: an economic analysis.
    Wu Y; Grunkemeier GL; Starr A
    J Thorac Cardiovasc Surg; 2007 Mar; 133(3):603-7. PubMed ID: 17320551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Quality-adjusted life years and Q-5D. An introduction].
    Henriksson M; Burström K
    Lakartidningen; 2006 May 31-Jun 6; 103(21-22):1734-9. PubMed ID: 16826718
    [No Abstract]   [Full Text] [Related]  

  • 26. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two studies find lack of benefit from hormone replacement therapy.
    Rollins G
    Rep Med Guidel Outcomes Res; 2003 Jun; 14(11):1-2, 5-6. PubMed ID: 12877113
    [No Abstract]   [Full Text] [Related]  

  • 28. Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis.
    Stevenson MD; Oakley J; Chilcott JB
    Med Decis Making; 2004; 24(1):89-100. PubMed ID: 15005958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trial of synthetic steroid for preventing postmenopausal osteoporosis.
    Coope J
    Br Med J; 1980 Aug; 281(6237):456-7. PubMed ID: 7427322
    [No Abstract]   [Full Text] [Related]  

  • 30. A cost-utility analysis of chronic spinal pain treatment outcomes: converting SF-36 data into quality-adjusted life years.
    Hatten AL; Gatchel RJ; Polatin PB; Stowell AW
    Clin J Pain; 2006 Oct; 22(8):700-11. PubMed ID: 16988566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of aortic valve replacement in the elderly: an introductory study.
    Wu Y; Jin R; Gao G; Grunkemeier GL; Starr A
    J Thorac Cardiovasc Surg; 2007 Mar; 133(3):608-13. PubMed ID: 17320552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterizing preferences for health outcomes in economic evaluations.
    Tosteson AN
    J Rheumatol Suppl; 2003 Dec; 68():15-8. PubMed ID: 14725249
    [No Abstract]   [Full Text] [Related]  

  • 33. Carcinoma of the endometrium in patients treated with tibolone.
    Yazigi R; Sahid S; Contreras L; Rodriguez T
    Gynecol Oncol; 2004 May; 93(2):568-70. PubMed ID: 15099984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-utility analysis and quality adjusted life years.
    Joish VN; Oderda GM
    J Pain Palliat Care Pharmacother; 2005; 19(1):57-61. PubMed ID: 15814516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-related quality of life after stroke: review of the literature and implications for future research.
    Tseng MC; Lin HJ
    Acta Neurol Taiwan; 2007 Mar; 16(1):7-12. PubMed ID: 17486727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of hip or knee replacement surgery in terms of quality-adjusted life years and costs.
    Räsänen P; Paavolainen P; Sintonen H; Koivisto AM; Blom M; Ryynänen OP; Roine RP
    Acta Orthop; 2007 Feb; 78(1):108-15. PubMed ID: 17453401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of influenza symptoms in healthy children: cost-effectiveness of rapid testing and antiviral therapy.
    Rothberg MB; Fisher D; Kelly B; Rose DN
    Arch Pediatr Adolesc Med; 2005 Nov; 159(11):1055-62. PubMed ID: 16275797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comments on the Prosser et Al approach to value disease reduction in children.
    Beutels P; Viney RC
    Pediatrics; 2004 Nov; 114(5):1375; author reply 1375-6. PubMed ID: 15520142
    [No Abstract]   [Full Text] [Related]  

  • 39. Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany.
    Brennan A; Ara R; Sterz R; Matiba B; Bergemann R
    Eur J Health Econ; 2006 Dec; 7(4):276-84. PubMed ID: 17063345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is Livial diabetogenic?
    Atsma WJ
    Maturitas; 1994 Oct; 19(3):239-40. PubMed ID: 7799830
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.